[{"NetIncomeLoss_1_Q1_USD":77000000.0,"RepaymentsOfLongTermDebt_1_Q1_USD":0.0,"CommitmentsAndContingencies_0_Q1_USD":null,"ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1_Q1_USD":-60000000.0,"LiabilitiesNoncurrent_0_Q1_USD":25940000000.0,"InventoryFinishedGoodsNetOfReserves_0_Q1_USD":2253000000.0,"BusinessCombinationContingentConsiderationLiability_0_Q1_USD":246000000.0,"IncreaseDecreaseInOperatingCapital_1_Q1_USD":1076000000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":-2534000000.0,"OtherInventoryInTransit_0_Q1_USD":193000000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":508000000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q1_USD":null,"ProceedsFromDivestitureOfBusinesses_1_Q1_USD":138000000.0,"GeneralAndAdministrativeExpense_1_Q1_USD":290000000.0,"GoodwillForeignCurrencyTranslationGainLoss_1_Q1_USD":322000000.0,"AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_0_Q1_USD":87000000.0,"LongTermDebtCurrent_0_Q1_USD":2674000000.0,"RestructuringCharges_1_Q1_USD":81000000.0,"CostOfGoodsAndServicesSold_1_Q1_USD":2104000000.0,"FairValueNetAssetLiability_0_Q1_USD":1725000000.0,"TreasuryStockShares_0_Q1_shares":106000000.0,"SellingAndMarketingExpense_1_Q1_USD":585000000.0,"LossContingencyAccrualAtCarryingValue_0_Q1_USD":1730000000.0,"GoodwillImpairedAccumulatedImpairmentLoss_0_Q1_USD":25600000000.0,"TreasuryStockValue_0_Q1_USD":4128000000.0,"CommonStockSharesIssued_0_Q1_shares":1208000000.0,"InventoryWorkInProcessNetOfReserves_0_Q1_USD":663000000.0,"AssetsCurrent_0_Q1_USD":12401000000.0,"DepreciationAndAmortization_1_Q1_USD":376000000.0,"NetIncomeLossAttributableToNoncontrollingInterest_1_Q1_USD":7000000.0,"Liabilities_0_Q1_USD":38029000000.0,"DerivativeLossOnDerivative_1_Q1_USD":493000000.0,"OtherOperatingIncomeExpenseNet_1_Q1_USD":5000000.0,"DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_0_Q1_USD":2000000.0,"ValuationAllowancesAndReservesDeductions_1_Q1_USD":3628000000.0,"FiniteLivedIntangibleAssetsAccumulatedAmortization_0_Q1_USD":12192000000.0,"EarningsPerShareBasic_1_Q1_USD":0.07,"MinorityInterest_0_Q1_USD":975000000.0,"AdjustmentForAmortization_1_Q1_USD":242000000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1_Q1_USD":-44000000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":1107000000.0,"PrepaidExpenseCurrent_0_Q1_USD":942000000.0,"AccountsReceivableNetCurrent_0_Q1_USD":4572000000.0,"IncomeTaxExpenseBenefit_1_Q1_USD":62000000.0,"NumberOfReportableSegments_1_Q1_Segment":3.0,"CommonStockValue_0_Q1_USD":57000000.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1_Q1_USD":254000000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":-493000000.0,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1_Q1_USD":3000000.0,"SeniorNotes_0_Q1_USD":25041000000.0,"AssetsFairValueAdjustment_1_Q1_USD":-14000000.0,"OtherAssetsCurrent_0_Q1_USD":652000000.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-57000000.0,"AmortizationOfIntangibleAssets_1_Q1_USD":242000000.0,"OtherAssetsNoncurrent_0_Q1_USD":524000000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":1743000000.0,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":441000000.0,"ProceedsFromSaleMaturityAndCollectionsOfInvestments_1_Q1_USD":44000000.0,"DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_0_Q1_USD":99000000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1_Q1_USD":-117000000.0,"Assets_0_Q1_USD":49004000000.0,"ShareBasedCompensation_1_Q1_USD":31000000.0,"EarningsPerShareDiluted_1_Q1_USD":0.07,"DebtInstrumentFairValue_0_Q1_USD":25027000000.0,"IncomeLossFromEquityMethodInvestments_1_Q1_USD":3000000.0,"OtherOperatingActivitiesCashFlowStatement_1_Q1_USD":-10000000.0,"TangibleAssetImpairmentCharges_1_Q1_USD":48000000.0,"Goodwill_0_Q1_USD":20302000000.0,"ImpairmentOfLongLivedAssetsToBeDisposedOf_1_Q1_USD":247000000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":31000000.0,"ValuationAllowancesAndReservesBalance_0_Q1_USD":4662000000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q1_USD":-208000000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-405000000.0,"InventoryRawMaterialsNetOfReserves_0_Q1_USD":1297000000.0,"DeferredTaxAndOtherLiabilitiesNoncurrent_0_Q1_USD":991000000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":1099000000.0,"LiabilitiesCurrent_0_Q1_USD":12089000000.0,"NonoperatingIncomeExpense_1_Q1_USD":-290000000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q1_USD":1743000000.0,"GrossProfit_1_Q1_USD":1878000000.0,"FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_1_Q1_USD":-9000000.0,"AdditionalPaidInCapital_0_Q1_USD":27474000000.0,"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0_Q1_USD":10975000000.0,"FiniteLivedIntangibleAssetsNet_0_Q1_USD":8445000000.0,"LongTermNotesAndLoans_0_Q1_USD":22288000000.0,"LineOfCreditFacilityMaximumBorrowingCapacity_0_Q1_USD":2300000000.0,"ProceedsFromPaymentsForOtherFinancingActivities_1_Q1_USD":-2000000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":6112000000.0,"ImpairmentOfIntangibleAssetsExcludingGoodwill_1_Q1_USD":79000000.0,"AssetImpairmentCharges_1_Q1_USD":127000000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":-434000000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-10869000000.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":529000000.0,"DeferredIncomeTaxAssetsNet_0_Q1_USD":691000000.0,"CommonStockParOrStatedValuePerShare_0_Q1_CHF":0.1,"OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_1_Q1_USD":-7000000.0,"LitigationSettlementExpense_1_Q1_USD":104000000.0,"CommonStockSharesAuthorized_0_Q1_shares":2495000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":3982000000.0,"ImpairmentOfLongLivedAssetsHeldForUse_1_Q1_USD":48000000.0,"OperatingIncomeLoss_1_Q1_USD":434000000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1_Q1_USD":144000000.0,"AccountsPayableTradeCurrent_0_Q1_USD":1692000000.0,"InventoryNet_0_Q1_USD":4406000000.0,"RestructuringReserve_0_Q1_USD":168000000.0,"FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0_Q1_USD":245000000.0,"FiniteLivedIntangibleAssetsGross_0_Q1_USD":20637000000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":49004000000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q1_USD":526000000.0,"DeferredFinanceCostsNoncurrentNet_0_Q1_USD":80000000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":0.07,"ProfitLoss_1_Q1_USD":84000000.0,"OtherLiabilitiesNoncurrent_0_Q1_USD":2220000000.0,"OtherLiabilitiesCurrent_0_Q1_USD":739000000.0,"StockholdersEquity_0_Q1_USD":10000000000.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":150000000.0,"AllowanceForDoubtfulAccountsReceivableCurrent_0_Q1_USD":119000000.0,"DebtCurrent_0_Q1_USD":2697000000.0,"DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_0_Q1_USD":0.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q1_USD":-201000000.0,"EntityCommonStockSharesOutstanding_0_Q1_shares":1102349072.0,"Ticker":"TEVA","CIK":"818686","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","OfficialName":"Teva Pharmaceutical Industries Limited American Depositary Shares","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"11303387401.0","Country":"Israel","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20210428"}]